NCT00568633: Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML |
|
|
| Terminated | 3 | 58 | US | Allogeneic HSCT, Hematopoietic stem cell transplantation (HSCT), Peripheral blood stem cell (PBSC) transplantation, Anti-thymocyte globulin (ATG), Thymoglobulin, Anti-thymocyte globulin (rabbit) (ATG), Cyclosporine (CSP), Ciclosporin, cyclosporin A, cyclosporin, Mycophenolate mofetil (MMF), Cellcept, Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Solumedrol, Medrol, Depo-Medrol, P-Care D40, P-Care D80, Best standard care, Standard of Care (physician discretion), Regular medical care | Stanford University, Genzyme, a Sanofi Company | Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML) | 12/15 | 12/15 | | |
